MIM
BBIO icon

MetLife Investment Management’s BridgeBio Pharma BBIO Stock Holding History

MetLife Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$673K Sell
9,031
-77,208
-90% -$5.41M ﹤0.01% 1753
2026
Q1 		$6.4M Sell
86,239
-1,371
-2% -$99.4K 0.03% 521
2025
Q4 		$6.7M Sell
87,610
-3,973
-4% -$261K 0.03% 495
2025
Q3 		$4.76M Sell
91,583
-1,560
-2% -$76.1K 0.02% 660
2025
Q2 		$4.02M Buy
93,143
+11,208
+14% +$408K 0.02% 672
2025
Q1 		$2.83M Sell
81,935
-4,028
-5% -$136K 0.02% 879
2024
Q4 		$2.36M Buy
85,963
+4,797
+6% +$124K 0.01% 956
2024
Q3 		$2.07M Hold
81,166
– – 0.01% 999
2024
Q2 		$2.06M Buy
81,166
+21,988
+37% +$601K 0.01% 954
2024
Q1 		$1.83M Sell
59,178
-1,212
-2% -$41.2K 0.01% 992
2023
Q4 		$2.44M Hold
60,390
– – 0.02% 872
2023
Q3 		$1.59M Hold
60,390
– – 0.01% 1006
2023
Q2 		$1.04M Buy
60,390
+4,719
+8% +$71K 0.01% 1250
2023
Q1 		$923K Sell
55,671
-2,773
-5% -$32.3K 0.01% 1256
2022
Q4 		$445K Hold
58,444
– – ﹤0.01% 1710
2022
Q3 		$581K Hold
58,444
– – ﹤0.01% 1527
2022
Q2 		$531K Hold
58,444
– – ﹤0.01% 1611
2022
Q1 		$593K Buy
58,444
+20,117
+52% +$206K ﹤0.01% 1667
2021
Q4 		$639K Hold
38,327
– – 0.01% 1376
2021
Q3 		$1.8M Hold
38,327
– – 0.02% 909
2021
Q2 		$2.34M Buy
38,327
+3,861
+11% +$220K 0.02% 813
2021
Q1 		$2.12M Buy
34,466
+4,605
+15% +$301K 0.02% 847
2020
Q4 		$2.12M Sell
29,861
-2,237
-7% -$108K 0.02% 792
2020
Q3 		$1.2M Hold
32,098
– – 0.01% 943
2020
Q2 		$1.05M Hold
32,098
– – 0.01% 1014
2020
Q1 		$931K Buy
32,098
+21,863
+214% +$678K 0.01% 934
2019
Q4 		$359K Sell
10,235
-4,682
-31% -$130K ﹤0.01% 1640
2019
Q3 		$320K Buy
+14,917
New +$413K ﹤0.01% 1668

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

MetLife Investment Management's BBIO Position: Q2 2026 in Review

MetLife Investment Management reduced its BridgeBio Pharma (BBIO) stake by 90% in Q2 2026, selling an estimated $5.41M and leaving 9,031 shares worth $673K. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

MetLife Investment Management first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $6.7M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • MetLife Investment Management held 9,031 shares of BridgeBio Pharma worth $673K as of Q2 2026.
  • MetLife Investment Management sold 77,208 BridgeBio Pharma shares in Q2 2026, an estimated $5.41M.
  • BridgeBio Pharma made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1753 holding.
  • MetLife Investment Management first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • MetLife Investment Management's BridgeBio Pharma position peaked at $6.7M in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.